ArticleJournal of translational medicine2021
Microspheres present comparable efficacy and safety profiles compared with polyvinyl alcohol for bronchial artery embolization treatment in hemoptysis patients.
Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- New insights on Bronchial Artery Embolization (BAE) for hemoptysis: a systematic review.BMC pulmonary medicine · 2025Pooled it
- A model for predicting the therapeutic efficacy of bronchial artery embolization in treating hemoptysis.Journal of cardiothoracic surgery · 2026Article
- Embosphere With or Without Coils in the Treatment of Hemoptysis: A Propensity-Matched Analysis of Recurrence and Safety.Canadian respiratory journal · 2026Article
- The correlation between systemic inflammatory index and rebleeding after bronchial artery embolization: a retrospective cohort study.International journal of emergency medicine · 2025Article
- Bronchial Artery Embolisation in Haemoptysis Management: A Scoping Review with Emphasis on Embolic Materials and Indications.Advances in respiratory medicine · 2025Article
- The effect of Angio-CT on the efficacy of hemoptysis patients with non-bronchial systemic arteries-a retrospective study.Cardiovascular diagnosis and therapy · 2025Article
- Advanced targeted microsphere embolization for arteriovenous malformations: state-of-the-art and future directions.Neuroradiology · 2025Review
- Development and validation of a novel nomogram for recurrent hemoptysis after bronchial artery embolization: a population-based cohort study.Frontiers in medicine · 2025Article
- The efficacy, safety, and related factors of bronchial artery embolization for hemoptysis: a systematic review and meta-analysis with subgroup analysis.Cardiovascular diagnosis and therapy · 2024Article
- The efficacy and safety of combined therapy with endobronchial tamponade and bronchial artery embolization for massive hemoptysis.BMC pulmonary medicine · 2024Article
- Embosphere microspheres size for bronchial artery embolization in patients with hemoptysis caused by bronchiectasis: a retrospective comparative analysis of 500-750 versus 700-900 μm microspheres.BMC pulmonary medicine · 2024Article
- A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study aimed to compare the efficacy and safety profiles of microspheres versus (vs.) polyvinyl alcohol (PVA) for bronchial artery embolization (BAE) treatment in patients with hemoptysis.
methodsTotally, 152 patients with hemoptysis who were about to receive BAE treatment were consecutively enrolled and divided into microspheres group (N = 62) and PVA group (N = 90). Technical success and clinical success were assessed after BAE procedure, and the hemoptysis-recurrence status, survival status and adverse events were recorded during follow-up.
resultsTechnical success rates were both 100% in microspheres group and PVA group; clinical success rate (96.8% vs. 100.0%, P = 0.165), 6-month (9.7% vs. 7.8%, P = 0.681) and 1-year (9.7% vs. 8.9%, P = 0.869) hemoptysis recurrence rate, 6-month (4.8% vs. 2.2%, P = 0.374) and 1-year (4.8% vs. 3.3%, P = 0.639) mortality were similar between microspheres group and PVA group. Furthermore, hemoptysis-free survival (P = 0.488) and overall survival (P = 0.321) were of no difference between two groups. In addition, all adverse events were mild, and there was no difference of adverse events between two groups (all P > 0.05). These data were validated by further multivariate regression analysis.
conclusionsMicrospheres present comparable efficacy and safety profiles compared with PVA for the BAE treatment in patients with hemoptysis, providing evidence for embolic agent selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.